Title : Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape.

Pub. Date : 2012 Nov

PMID : 22960555






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 SUMMARY: Small molecule inhibitors of BCR signaling kinases, Bruton"s tyrosine kinase (Btk) inhibitor ibrutinib and the phosphoinositide 3"-kinase delta (PI3Kdelta) inhibitor GS-1101, are currently transforming the landscape of CLL therapy. ibrutinib Bruton tyrosine kinase Homo sapiens